Strengthening Adult Immunization in India: PCV20 and the Changing Landscape of Pneumococcal Disease Prevention
World Immunization Week 2026, observed from 24 to 30 April under the theme “For every generation, vaccines work,” offers a timely opportunity to reflect on one of public health’s most enduring successes. Over decades, vaccination has quietly transformed population health—reducing mortality, preventing disability, and extending life expectancy across continents and age groups. From childhood immunization programmes to the growing emphasis on adult and life‑course vaccination, vaccines have consistently demonstrated their ability to protect individuals while delivering cumulative benefits to societies. Yet, the continued burden of vaccine‑preventable diseases reminds us that progress cannot be taken for granted. Persistent gaps in coverage, changing demographics, immunosenescence, and the rising prevalence of chronic conditions underscore the need to re‑frame immunization not as a one‑time early‑life intervention, but as an essential component of health at every stage of life. As we mark World Immunization Week 2026, the focus must extend beyond awareness—towards strengthening confidence, integrating vaccination into routine clinical care, and ensuring equitable access so that the promise of immunization truly endures for every generation.
Rising burden of vaccine-preventable diseases among Indian adults
In India, adults now account for approximately 95% of VPD-related mortality, indicating a substantial shift in the epidemiology of these diseases. 1 Adult immunization coverage remains poor, with estimates ranging from 1.5-2% among those over 45 years old. 2 Lower respiratory infections remain among the top causes of adult mortality. Seasonal influenza and COVID-19 have emphasized the vulnerability of older persons, with roughly 85% of COVID-19 deaths occurring in individuals ≥45 years old. 3-5 Chronic illnesses like hepatitis B and age-related conditions like herpes zoster contribute to this expanding burden. 6-7
Pneumococcal Disease: A Significant Public Health Concern
India accounts for roughly 23% of the worldwide pneumonia burden, with streptococcus pneumoniae being the major cause of community-acquired pneumonia (CAP) in adults. Invasive pneumococcal disease (IPD) has a high burden in elderly populations, with up to 28% of cases resulting in death. CAP mortality rates increase 2.5-3 times beyond 50 years, primarily due to immuno senescence and underlying comorbidities. 8-9 Furthermore, almost 90% of hospitalized individuals with pneumococcal disease between the ages of 50 and 64 have at least one chronic illness, underscoring the importance of focused prevention. 10
Expanding Immunization to Younger At-Risk Adults
Emerging evidence emphasizes the need of pneumococcal immunization for young individuals with comorbidities. Individuals aged 18 to 49 years with chronic diseases are roughly 2.9 times more likely to have pneumonia, whereas immunocompromised people are 4.2 times more likely. Diabetes significantly increases the risk of pneumococcal pneumonia and IPD mortality, emphasizing the importance of early vaccination in high-risk patients. 11
PCV20: An Expanded and Streamlined Immunization Approach
Adult vaccination has advanced significantly with the release of the 20-valent pneumococcal conjugate vaccine (PCV20). PCV20 offers comprehensive serotype coverage in a single dose, encompassing all PCV13 serotypes plus seven additional serotypes, in contrast to previous sequential regimens using PCV13 followed by PPSV23. 12 Adult pneumococcal immunization is currently recommended by the CDC and ACIP as PCV20, which eliminates the requirement for additional PPSV23 doses. 12-14 The Indian 2026 Consensus Guidelines have made PCV20 the recommended approach, streamlining immunization regimens and enhancing adherence.¹." This strategy supports a life-course approach to immunization, which is in line with the WHO Immunization Agenda 2030.¹."
Guidelines for the Use of PCV20 in Adults Vaccine Naive Individual
For routine protection, a single dose of PCV20 is advised for adults over 50. A single dose is recommended for adults between the ages of 18 and 49 who have risk factors, such as immunocompromising conditions, smoking, drinking, or chronic illnesses. 14-15
Adults with Prior Vaccinations
Updated guidelines for people who have already received vaccinations include: - Prior PPSV23 only: After at least a year, one dose of PCV20 is enough; no additional PPSV23 is needed. 1
-Prior PCV13 only: After at least a year, one dosage of PCV20. 1
- Prior PCV13 + PPSV23:
- For Immunocompetent àPCV20 can be given to adult ≥65 years. 12
- For Immunocompromised àPCV20 is advised at least five years following the last dose of PPSV23. 12 These suggestions provide a more efficient and adaptable immunization approach.
Conclusion
The growing burden of vaccine‑preventable diseases among adults in India highlights an urgent need to move beyond a childhood‑centric view of immunization. Ageing populations, immunosenescence, and the rising prevalence of chronic conditions are reshaping disease risk across adulthood, making prevention an essential component of routine care. In this context, World Immunization Week 2026, observed under the theme “For every generation, vaccines work,” reinforces a critical message: immunization must be viewed as a life‑course intervention, not a one‑time event. Evolving pneumococcal vaccination strategies, including simplified approaches such as single‑dose PCV20, reflect how scientific advances can support broader adult immunization uptake and programmatic feasibility. Strengthening adult vaccination, embedding guideline‑recommended vaccines into clinical practice, and ensuring equitable access are key to translating this theme into impact—so that the benefits of vaccines continue to protect health, reduce preventable morbidity and mortality, and endure across generations.
References
1. Dhawan AM, Desai A, Gvalani A, et al. Int J Community Med Public Health. 2025;12:1159–1165.
2. Rizvi AA, Singh A. Bull World Health Organ. 2022;100:375–384.
3. GBD 2023 Causes of Death Collaborators. Lancet. 2025;406:1811–1872.
4. National Centre for Disease Control. Seasonal influenza surveillance reports, India.
5. Ministry of Health & Family Welfare, India. COVID-19 age-wise mortality briefing; 2020.
6. World Health Organization. Global Hepatitis Report 2024.
7. Association of Physicians of India. Adult Immunization Guidelines. 2024.
8. Kumar R, Vora A, Rampal R, et al. J Assoc Physicians India. 2025;73(Suppl):35–38.
9. Singh D, Sinha A, Kanungo S, et al. Vaccines (Basel). 2022;10:2124.
10. Kobayashi M, Leidner AJ, Gierke R, et al. MMWR. 2025;74:1–8.
11. Silverii GA, Gabutti G, Tafuri S, et al. Acta Diabetol. 2024;61:1029–1039.
12. Kobayashi M, Farrar JL, Gierke R, et al. MMWR. 2022;71:109–117.
13. Kobayashi M, Pilishvili T, et al. MMWR Recomm Rep. 2023;72:1–39.
14. Centers for Disease Control and Prevention. Summary of risk-based pneumococcal vaccination recommendations. 2026.
15. Vora A, Tiwaskar M, Lele J, et al. Indian Consensus Guidelines on Adult Immunization 2026.
